Full Text Journal Articles by
Author Shogo Shigeta

Advertisement

Find full text journal articles








The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines evaluation committee.

Masae Ikeda, Masako Shida, Shogo Shigeta, Satoru Nagase, Fumiaki Takahashi, Wataru Yamagami, Hidetaka Katabuchi, Nobuo Yaegashi, Daisuke Aoki, Mikio Mikami,

<h4>Objective</h4>The Japan Society of Gynecologic Oncology published the first guidelines for the treatment of cervical cancer in 2007. The aim of this research was to evaluate the influence of the introduction of the first guideline on clinical trends and outcomes of patients with early-stage cervical cancer who underwent surgery.<h4>Methods</h4>This analysis ... Read more >>

J Gynecol Oncol (Journal of gynecologic oncology)
[2021, 32(3):e44]

Cited: 0 times

View full text PDF listing >>



Prospective evaluation of sentinel node navigation surgery in Japanese patients with low-risk endometrial cancer-safety and occurrence of lymphedema.

Hitoshi Niikura, Asami Toki, Tomoyuki Nagai, Satoshi Okamoto, Shogo Shigeta, Hideki Tokunaga, Muneaki Shimada, Mika Watanabe, Nobuo Yaegashi,

<h4>Objective</h4>The present study aimed to clarify the occurrence rate of lymphedema and prognosis in patients with endometrial cancer according to sentinel lymph node biopsy alone with intraoperative histopathological examination.<h4>Methods</h4>The study included 45 consecutive patients with endometrial cancer treated at Tohoku University Hospital between October 2014 and August 2017. All patients ... Read more >>

Jpn J Clin Oncol (Japanese journal of clinical oncology)
[2021, 51(4):584-589]

Cited: 0 times

View full text PDF listing >>



Advertisement

Involvement of small extracellular vesicle-derived TIE-1 in the chemoresistance of ovarian cancer cells.

Tomoka Misawa, Masafumi Toyoshima, Kazuyuki Kitatani, Masumi Ishibashi, Junko Hasegawa-Minato, Shogo Shigeta, Nobuo Yaegashi,

<h4>Background</h4>Ovarian cancer is the most lethal gynecologic malignancy due to the tumor's acquisition of chemoresistance to platinum-based chemotherapy. To solve this problem, we conducted RNAi-based large-scale screening and determined that tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE-1) is a key molecule involved in the platinum resistance of ovarian ... Read more >>

Cancer Treat Res Commun (Cancer treatment and research communications)
[2021, 27:100364]

Cited: 0 times

View full text PDF listing >>



Ceramide synthase 2-C24:1 -ceramide axis limits the metastatic potential of ovarian cancer cells.

Xuewei Zhang, Wataru Sakamoto, Daniel Canals, Masumi Ishibashi, Masaya Matsuda, Kentaro Nishida, Masafumi Toyoshima, Shogo Shigeta, Makoto Taniguchi, Can E Senkal, Toshiro Okazaki, Nobuo Yaegashi, Yusuf A Hannun, Takeshi Nabe, Kazuyuki Kitatani,

Regulation of sphingolipid metabolism plays a role in cellular homeostasis, and dysregulation of these pathways is involved in cancer progression. Previously, our reports identified ceramide as an anti-metastatic lipid. In the present study, we investigated the biochemical alterations in ceramide-centered metabolism of sphingolipids that were associated with metastatic potential. We ... Read more >>

FASEB J (FASEB journal : official publication of the Federation of American Societies for Experimental Biology)
[2021, 35(2):e21287]

Cited: 0 times

View full text PDF listing >>



Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma.

Shogo Shigeta, Goldie Y L Lui, Reid Shaw, Russell Moser, Kay E Gurley, Grace Durenberger, Rachele Rosati, Robert L Diaz, Tan A Ince, Elizabeth M Swisher, Carla Grandori, Christopher J Kemp,

Ovarian clear cell carcinoma (OCCC) is a rare, chemo-resistant subtype of ovarian cancer. To identify novel therapeutic targets and combination therapies for OCCC, we subjected a set of patient-derived ovarian cancer cell lines to arrayed high-throughput siRNA and drug screening. The results indicated OCCC cells are vulnerable to knockdown of ... Read more >>

Mol Cancer Ther (Molecular cancer therapeutics)
[2021, 20(4):691-703]

Cited: 0 times

View full text PDF listing >>



Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).

Hideki Tokunaga, Keita Iida, Atsushi Hozawa, Soichi Ogishima, Yoh Watanabe, Shogo Shigeta, Muneaki Shimada, Yumi Yamaguchi-Kabata, Shu Tadaka, Fumiki Katsuoka, Shin Ito, Kazuki Kumada, Yohei Hamanaka, Nobuo Fuse, Kengo Kinoshita, Masayuki Yamamoto, Nobuo Yaegashi, Jun Yasuda,

Identification of the population frequencies of definitely pathogenic germline variants in two major hereditary breast and ovarian cancer syndrome (HBOC) genes, BRCA1/2, is essential to estimate the number of HBOC patients. In addition, the identification of moderately penetrant HBOC gene variants that contribute to increasing the risk of breast and ... Read more >>

PLoS One (PloS one)
[2021, 16(1):e0236907]

Cited: 0 times

View full text PDF listing >>



MicroRNA Let-7c Contributes to Paclitaxel Resistance via Aurora-B in Endometrial Serous Carcinoma.

Izumi Sato, Masumi Ishibashi, Hideki Tokunaga, Shogo Shigeta, Shoko Sakurada, Muneaki Shimada, Satoru Nagase, Yoh Watanabe, Nobuo Yaegashi,

The incidence of endometrial cancer has rapidly risen over recent years. Paclitaxel, a key drug for endometrial cancer treatment, inhibits microtubule depolymerization and induces apoptosis in cancer cells. Endometrial serous carcinoma (ESC) accounts for < 10% of all endometrial carcinomas, but its aggressive nature makes it responsible for close to ... Read more >>

Tohoku J Exp Med (The Tohoku journal of experimental medicine)
[2020, 251(4):263-272]

Cited: 1 time

View full text PDF listing >>



Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes in a 3,552 Japanese whole-genome sequence dataset (3.5KJPNv2)

Hideki Tokunaga, Keita Iida, Atsushi Hozawa, Soichi Ogishima, Yoh Watanabe, Shogo Shigeta, Muneaki Shimada, Yumi Yamaguchi-Kabata, Shu Tadaka, Fumiki Katsuoka, Shin Ito, Kazuki Kumada, Yohei Hamanaka, Nobuo Fuse, Kengo Kinoshita, Masayuki Yamamoto, Nobuo Yaegashi, Jun Yasuda,

Identification of pathogenic germline variants yet no clinical evidence in BRCA genes has become important in patient care of hereditary breast and ovarian cancer syndrome (HBOC). Computational scoring and prospective cohort studies may help to identify such pathogenic variants. We annotated the variants in the BRCA1 and BRCA2 genes from ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Epidemiological guideline influence on the therapeutic trend and patient outcome of uterine cervical cancer in Japan: Japan society of gynecologic oncology guideline evaluation committee project.

Shogo Shigeta, Masako Shida, Satoru Nagase, Masae Ikeda, Fumiaki Takahashi, Takeo Shibata, Wataru Yamagami, Hidetaka Katabuchi, Nobuo Yaegashi, Daisuke Aoki, Mikio Mikami,

<h4>Objective</h4>The Japan Society of Gynecologic Oncology published its first clinical guidelines for uterine cervical cancer in 2007 which has been revised twice in 2011 and 2017. The aim of this study was to investigate the influence of the first guideline publication on the therapeutic trend and patient outcome by analyzing ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2020, 159(1):248-255]

Cited: 0 times

View full text PDF listing >>



Potential of Tyrosine Kinase Receptor TIE-1 as Novel Therapeutic Target in High-PI3K-Expressing Ovarian Cancer.

Xuewei Zhang, Masumi Ishibashi, Kazuyuki Kitatani, Shogo Shigeta, Hideki Tokunaga, Masafumi Toyoshima, Muneaki Shimada, Nobuo Yaegashi,

Tyrosine kinase receptor TIE-1 plays a critical role in angiogenesis and blood-vessel stability. In recent years, increased TIE-1 expression has been observed in many types of cancers; however, the biological significance and underlying mechanisms remain unknown. Thus, in the present study, we investigated the tumor biological functions of TIE-1 in ... Read more >>

Cancers (Basel) (Cancers)
[2020, 12(6):]

Cited: 0 times

View full text PDF listing >>



Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan.

Mamiko Onuki, Koji Matsumoto, Takashi Iwata, Kasumi Yamamoto, Yoichi Aoki, Shoji Maenohara, Naotake Tsuda, Shoji Kamiura, Kazuhiro Takehara, Koji Horie, Nobutaka Tasaka, Hideaki Yahata, Yuji Takei, Yoichi Aoki, Hisamori Kato, Takeshi Motohara, Keiichiro Nakamura, Mitsuya Ishikawa, Tatsuya Kato, Hiroyuki Yoshida, Noriomi Matsumura, Hidekatsu Nakai, Shogo Shigeta, Fumiaki Takahashi, Kiichiro Noda, Nobuo Yaegashi, Hiroyuki Yoshikawa,

To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012-2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2-3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), ... Read more >>

Cancer Sci (Cancer science)
[2020, 111(7):2546-2557]

Cited: 1 time

View full text PDF listing >>



Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer.

Takafumi Watanabe, Shu Soeda, Hiroshi Nishiyama, Yuichiroh Kiko, Hideki Tokunaga, Shogo Shigeta, Nobuo Yaegashi, Hidekazu Yamada, Tsuyoshi Ohta, Satoru Nagase, Tadahiro Shoji, Masahiro Kagabu, Tsukasa Baba, Dai Shimizu, Naoki Sato, Yukihiro Terada, Masayuki Futagami, Yoshihito Yokoyama, Keiya Fujimori,

The aim of the present study was to evaluate the oncologic safety and reproductive outcome in patients with stage I epithelial ovarian cancer (EOC) treated with fertility-sparing surgery (FSS). Women aged ≤40 years with stage I EOC who had undergone FSS between 2000 and 2010 were retrospectively reviewed. Survival was ... Read more >>

Mol Clin Oncol (Molecular and clinical oncology)
[2020, 12(1):44-50]

Cited: 2 times

View full text PDF listing >>



La-Related Protein 4 as a Suppressor for Motility of Ovarian Cancer Cells.

Mahy Egiz, Toshinori Usui, Masumi Ishibashi, Xuewei Zhang, Shogo Shigeta, Masafumi Toyoshima, Kazuyuki Kitatani, Nobuo Yaegashi,

The La-related proteins (LARPs) are a family of RNA binding proteins that control the degradation and stabilization of RNAs. As emerging research reveals the biology of each LARP, it is evident that LARPs are dysregulated in some types of cancer. Upregulation of cell motility potentiates the metastatic potential of ovarian ... Read more >>

Tohoku J Exp Med (The Tohoku journal of experimental medicine)
[2019, 247(1):59-67]

Cited: 1 time

View full text PDF listing >>



Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.

Masumi Ishibashi, Masafumi Toyoshima, Xuewei Zhang, Junko Hasegawa-Minato, Shogo Shigeta, Toshinori Usui, Christopher J Kemp, Carla Grandori, Kazuyuki Kitatani, Nobuo Yaegashi,

Platinum resistance is one of the most challenging problems in ovarian cancer treatment. High-throughput functional siRNA screening identified tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE-1) as a gene that confers cells resistant to cisplatin. Conversely enforced over-expression of TIE-1 was validated to decrease cisplatin sensitivity in multiple ovarian ... Read more >>

Sci Rep (Scientific reports)
[2018, 8(1):13207]

Cited: 4 times

View full text PDF listing >>



Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel.

Manabu Seino, Tsuyoshi Ohta, Akiko Sugiyama, Hirotsugu Sakaki, Takeshi Sudo, Seiji Tsutsumi, Shogo Shigeta, Hideki Tokunaga, Masafumi Toyoshima, Nobuo Yaegashi, Satoru Nagase,

<h4>Introduction</h4>Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel.<h4>Results</h4>Glutathione (GSH) concentration in PTX-1 cells was higher than in USPC-1 cells. In addition, GSH concentration in the USPC-1 ... Read more >>

Oncotarget (Oncotarget)
[2018, 9(62):31985-31998]

Cited: 2 times

View full text PDF listing >>



Novel cooperative pathway of c-Myc and Furin, a pro-protein convertase, in cell proliferation as a therapeutic target in ovarian cancers.

Junko Hasegawa-Minato, Masafumi Toyoshima, Masumi Ishibashi, Xuewei Zhang, Shogo Shigeta, Carla Grandori, Kazuyuki Kitatani, Nobuo Yaegashi,

c-Myc is a master regulator of various oncogenic functions in many types of human cancers. However, direct c-Myc-targeted therapy has not been successful in the clinic. Here, we explored a novel therapeutic target, which shows synthetic lethality in c-Myc-driven ovarian cancers, and examined the molecular mechanism of the synthetic lethal ... Read more >>

Oncotarget (Oncotarget)
[2018, 9(3):3483-3496]

Cited: 1 time

View full text PDF listing >>



Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer.

Xuewei Zhang, Kazuyuki Kitatani, Masafumi Toyoshima, Masumi Ishibashi, Toshinori Usui, Junko Minato, Mahy Egiz, Shogo Shigeta, Todd Fox, Tye Deering, Mark Kester, Nobuo Yaegashi,

Ceramides are bioactive lipids that mediate cell death in cancer cells, and ceramide-based therapy is now being tested in dose-escalating phase I clinical trials as a cancer treatment. Multiple nanoscale delivery systems for ceramide have been proposed to overcome the inherent toxicities, poor pharmacokinetics, and difficult biophysics associated with ceramide. ... Read more >>

Mol Cancer Ther (Molecular cancer therapeutics)
[2018, 17(1):50-59]

Cited: 10 times

View full text PDF listing >>



Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee.

Shogo Shigeta, Satoru Nagase, Satoru Nagase, Mikio Mikami, Masae Ikeda, Masako Shida, Isao Sakaguchi, Norichika Ushioda, Fumiaki Takahashi, Wataru Yamagami, Nobuo Yaegashi, Yasuhiro Udagawa, Hidetaka Katabuchi,

<h4>Objective</h4>The Japan Society of Gynecologic Oncology (JSGO) published the first practice guideline for endometrial cancer in 2006. The JSGO guideline evaluation committee assessed the effect of this guideline introduction on clinical practice and patient outcome using data provided by the Japan Society of Obstetrics and Gynecology (JSOG) cancer registration system.<h4>Methods</h4>Data ... Read more >>

J Gynecol Oncol (Journal of gynecologic oncology)
[2017, 28(6):e76]

Cited: 2 times

View full text PDF listing >>



Eccrine porocarcinoma of the vulva: a case report and review of the literature.

Ayako Fujimine-Sato, Masafumi Toyoshima, Shogo Shigeta, Asami Toki, Takashi Kuno, Izumi Sato, Mika Watanabe, Hitoshi Niikura, Nobuo Yaegashi,

<h4>Background</h4>Malignant tumors arising from the vulva account for only 0.6 % of all cancers in female patients. The predominant histologic type, representing about 90 % of these malignancies, is squamous cell carcinoma. Eccrine porocarcinoma is a rare malignant tumor arising from sweat glands. The incidence of eccrine porocarcinoma is estimated at 0.005-0.01 % ... Read more >>

J Med Case Rep (Journal of medical case reports)
[2016, 10(1):319]

Cited: 2 times

View full text PDF listing >>



Leptomeningeal metastasis from gynecologic cancers diagnosed by brain MRI.

Masafumi Toyoshima, Keita Tsuji, Shogo Shigeta, Hideki Tokunaga, Kiyoshi Ito, Yoh Watanabe, Kosuke Yoshinaga, Takeo Otsuki, Hitoshi Niikura, Nobuo Yaegashi,

Leptomeningeal metastasis (LM) is rarely observed in gynecologic cancers. As gadolinium-enhanced magnetic resonance imaging (Gd-MRI) is highly effective for diagnosing LM, the aim of this study is to describe the clinical behaviors and outcomes of LM patients who were diagnosed by Gd-MRI. After securing institutional review board approvals, we retrospectively ... Read more >>

Clin Imaging (Clinical imaging)
[2017, 41:42-47]

Cited: 3 times

View full text PDF listing >>



Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid.

K Kitatani, T Usui, S K Sriraman, M Toyoshima, M Ishibashi, S Shigeta, S Nagase, M Sakamoto, H Ogiso, T Okazaki, Y A Hannun, V P Torchilin, N Yaegashi,

Targeting cell motility, which is required for dissemination and metastasis, has therapeutic potential for ovarian cancer metastasis, and regulatory mechanisms of cell motility need to be uncovered for developing novel therapeutics. Invasive ovarian cancer cells spontaneously formed protrusions, such as lamellipodia, which are required for generating locomotive force in cell ... Read more >>

Oncogene (Oncogene)
[2016, 35(21):2801-2812]

Cited: 22 times

View full text PDF listing >>



Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.

Satsuki Mashiko, Kazuyuki Kitatani, Masafumi Toyoshima, Atsuhiko Ichimura, Takashi Dan, Toshinori Usui, Masumi Ishibashi, Shogo Shigeta, Satoru Nagase, Toshio Miyata, Nobuo Yaegashi,

Plasminogen activator inhibitor (PAI)-1 is predictive of poor outcome in several types of cancer. The present study investigated the biological role for PAI-1 in ovarian cancer and potential of targeted pharmacotherapeutics. In patients with ovarian cancer, PAI-1 mRNA expression in tumor tissues was positively correlated with poor prognosis. To determine ... Read more >>

Cancer Biol Ther (Cancer biology & therapy)
[2015, 16(2):253-260]

Cited: 23 times

View full text PDF listing >>



Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.

Tadao Takano, Hitoshi Niikura, Kiyoshi Ito, Satoru Nagase, Hiroki Utsunomiya, Takeo Otsuki, Masafumi Toyoshima, Hideki Tokunaga, Michiko Kaiho-Sakuma, Naomi Shiga, Tomoyuki Nagai, Sota Tanaka, Ai Otsuki, Hiroki Kurosawa, Shogo Shigeta, Keita Tsuji, Takuhiro Yamaguchi, Nobuo Yaegashi,

<h4>Background</h4>Uterine leiomyosarcoma (LMS) and undifferentiated endometrial sarcoma (UES) are rare, aggressive malignancies. Both are treated similarly; however, few chemotherapy agents are effective. Recently, the combination of gemcitabine (900 mg/m(2), days 1 and 8) plus docetaxel (100 mg/m(2), day 8) with granulocyte colony-stimulating factor (G-CSF, 150 μg/m(2), days 9-15) has been ... Read more >>

Int J Clin Oncol (International journal of clinical oncology)
[2014, 19(5):897-905]

Cited: 8 times

View full text PDF listing >>



[Diagnosis and treatment of uterine leiomyosarcoma].

Shogo Shigeta, Satoru Nagase, Nobuo Yaegashi,

Nihon Rinsho (Nihon rinsho. Japanese journal of clinical medicine)
[2012, 70 Suppl 4:452-455]

Cited: 0 times

View full text PDF listing >>





Advertisement

Disclaimer
1.0124 s